ArticleBritish journal of pharmacology2008
CGRP blockers in migraine therapy: where do they act?
Article in British journal of pharmacology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 86 citations in OpenAlex.
- The effect and safety of monoclonal antibodies to calcitonin gene-related peptide and its receptor on migraine: a systematic review and meta-analysis.The journal of headache and pain · 2017Pooled it
- Osteochondrosis in horses: An overview of genetic and other factors.Equine veterinary journal · 2026Review
- Molecular Mechanisms of Migraine: Nitric Oxide Synthase and Neuropeptides.International journal of molecular sciences · 2023Review
- CGRP physiology, pharmacology, and therapeutic targets: migraine and beyond.Physiological reviews · 2023Review
- CGRP-dependent sensitization of PKC-δ positive neurons in central amygdala mediates chronic migraine.The journal of headache and pain · 2022Article
- Sustained Activation of CLR/RAMP Receptors by Gel-Forming Agonists.International journal of molecular sciences · 2022Article
- Gel-forming antagonist provides a lasting effect on CGRP-induced vasodilation.Frontiers in pharmacology · 2022Article
- Breakthroughs on the clinical management of headache and questions that need to be solved.Ibrain · 2021Review
- Role of Calcitonin Gene-Related Peptide in Nociceptive Modulationin Anterior Cingulate Cortex of Naïve Rats and Rats With Inflammatory Pain.Frontiers in pharmacology · 2020Article
- Article
- Vascular Contributions to Migraine: Time to Revisit?Frontiers in cellular neuroscience · 2018Article
- Triptans and CGRP blockade - impact on the cranial vasculature.The journal of headache and pain · 2017Review
- Induction of Migraine-Like Photophobic Behavior in Mice by Both Peripheral and Central CGRP Mechanisms.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2017Article
- Commentary: Cholinergic Nociceptive Mechanisms in Rat Meninges and Trigeminal Ganglia: Potential Implications for Migraine Pain.Frontiers in neurology · 2017Article
- CGRP as a neuropeptide in migraine: lessons from mice.British journal of clinical pharmacology · 2015Review
- CGRP mechanism antagonists and migraine management.Current neurology and neuroscience reports · 2015Review
- Kynurenic acid modulates experimentally induced inflammation in the trigeminal ganglion.The journal of headache and pain · 2015Article
- Calcitonin gene-related peptide (CGRP): a new target for migraine.Annual review of pharmacology and toxicology · 2015Review
- The role of the blood-brain barrier in the development and treatment of migraine and other pain disorders.Frontiers in cellular neuroscience · 2014Review
- The calcitonin gene-related peptide receptor antagonist MK-8825 decreases spinal trigeminal activity during nitroglycerin infusion.The journal of headache and pain · 2013Article
Corrections and comments
- Comment on
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Calcitonin gene-related peptide (CGRP) is expressed throughout the CNS and peripheral nervous system, consistent with control of vasodilatation, nociception, motor function, secretion and olfaction. AlphaCGRP is prominently localized in primary afferent C and Adelta fibres of spinal and trigeminal ganglia. Activation of the trigeminal nerve results in antidromic release of CGRP, acting through a CGRP1 receptor. Antagonists of CGRP1 receptors reduce signalling in the trigeminovascular pathway at multiple sites, putatively inside the blood-brain barrier. Other ways of interacting with CGRP mechanisms have appeared limiting the availability of CGRP in the circulation with a specific CGRP antibody or with a CGRP-binding RNA-Spiegelmer. Either way reduces neurogenic inflammation and attenuates signalling within the trigeminovascular pathway. Specific CGRP receptor blockade has been shown to reduce the effect of released CGRP and to abort acute migraine attacks. The novel approach of reducing available CGRP is limited by the blood-brain barrier; its usefulness may be more as prophylaxis rather than as acute treatment of migraine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.